Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E4GG
|
||||
| Former ID |
DCL000620
|
||||
| Drug Name |
Resatorvid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Sepsis [ICD9: 995.91; ICD10:A40, A41] | Phase 3 | [522254] | ||
| Company |
Takeda
|
||||
| Formula |
C15H17ClFNO4S
|
||||
| Canonical SMILES |
CCOC(=O)C1=CCCCC1S(=O)(=O)NC2=C(C=C(C=C2)F)Cl
|
||||
| InChI |
1S/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-7-10(17)9-12(13)16/h5,7-9,14,18H,2-4,6H2,1H3/t14-/m1/s1
|
||||
| InChIKey |
LEEIJTHMHDMWLJ-CQSZACIVSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Toll-like receptor 4 | Target Info | Antagonist | [536637], [551717], [551795] | |
| KEGG Pathway | NF-kappa B signaling pathway | ||||
| HIF-1 signaling pathway | |||||
| Phagosome | |||||
| PI3K-Akt signaling pathway | |||||
| Toll-like receptor signaling pathway | |||||
| Pathogenic Escherichia coli infection | |||||
| Salmonella infection | |||||
| Pertussis | |||||
| Legionellosis | |||||
| Leishmaniasis | |||||
| Chagas disease (American trypanosomiasis) | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Amoebiasis | |||||
| Tuberculosis | |||||
| Hepatitis B | |||||
| Measles | |||||
| Influenza A | |||||
| Proteoglycans in cancer | |||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| PANTHER Pathway | Toll receptor signaling pathway | ||||
| Pathway Interaction Database | Endogenous TLR signaling | ||||
| Reactome | Ligand-dependent caspase activation | ||||
| Toll Like Receptor 4 (TLR4) Cascade | |||||
| MyD88:Mal cascade initiated on plasma membrane | |||||
| MyD88-independent TLR3/TLR4 cascade | |||||
| TRIF-mediated programmed cell death | |||||
| MyD88 deficiency (TLR2/4) | |||||
| IRAK4 deficiency (TLR2/4) | |||||
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | |||||
| IKK complex recruitment mediated by RIP1 | |||||
| TRAF6 mediated induction of TAK1 complex | |||||
| WikiPathways | Toll-like receptor signaling pathway | ||||
| Toll-Like Receptors Cascades | |||||
| MyD88:Mal cascade initiated on plasma membrane | |||||
| MyD88-independent cascade | |||||
| Primary Focal Segmental Glomerulosclerosis FSGS | |||||
| Spinal Cord Injury | |||||
| Corticotropin-releasing hormone | |||||
| Pathogenic Escherichia coli infection | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| References | |||||
| Ref 536637 | TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol. 2008 Apr 14;584(1):40-8. Epub 2008 Feb 5. | ||||
| Ref 551717 | Clinical pipeline report, company report or official report of Takeda (2009). | ||||
| Ref 551795 | THE NOVEL SELECTIVE TOLL-LIKE RECEPTOR 4 SIGNAL TRANSDUCTION INHIBITOR TAK-242 PREVENTS ENDOTOXAEMIA IN CONSCIOUS GUINEA-PIGS. Clinical and Experimental Pharmacology and Physiology Volume 36, Issue 5-6, pages 589-593, May/June 2009 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.